Josje Altenburg1, Kim Wortel1, Casper S de Graaff1, Tjip S van der Werf2, Wim G Boersma1. 1. Department of Pulmonary Diseases, Alkmaar Medical Centre, Alkmaar, the Netherlands. 2. Department of Internal Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Abstract
BACKGROUND AND AIM: Quality of life in patients with non-cystic fibrosis (non-CF) bronchiectasis is largely defined by respiratory symptoms. To date, no disease-specific tool for symptom measurement in this patient group was available. We developed the lower respiratory tract infections - visual analogue scale (LRTI-VAS) in order to quickly and conveniently quantify symptoms in non-CF bronchiectasis. This study aimed to validate LRTI-VAS for use in non-CF bronchiectasis. METHODS: This study included outpatients with radiologically proven bronchiectasis and no evidence of CF. Results of LRTI-VAS were compared with other markers of disease activity {lung function parameters, oxygen saturation and three health-related quality of life questionnaires [Medical Outcomes Study Short-Form 36 Health Survey (SF-36), St Georges Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ)]} and validity, reliability and responsiveness were assessed. RESULTS: Thirty stable and 30 exacerbating participants completed the LRTI-VAS questionnaire. When testing for repeatability on two separate occasions, no statistically significant difference between total scores was found {1.4 [standard deviation (SD)] 5.3}, P = 0.16). Internal consistency was high across items (Cronbach's alpha 0.86). Correlation with SGRQ, SF-36 and LCQ total scores was high. Following antibiotic treatment, mean (SD) LRTI-VAS total score improved from 18.1 (SD 9.9) to 26.1 (SD 6.6) (P < 0.001). CONCLUSIONS: LRTI-VAS showed excellent validity, reliability and responsiveness to change and therefore appears a reliable tool for symptom measurement in non-CF bronchiectasis.
BACKGROUND AND AIM: Quality of life in patients with non-cystic fibrosis (non-CF) bronchiectasis is largely defined by respiratory symptoms. To date, no disease-specific tool for symptom measurement in this patient group was available. We developed the lower respiratory tract infections - visual analogue scale (LRTI-VAS) in order to quickly and conveniently quantify symptoms in non-CF bronchiectasis. This study aimed to validate LRTI-VAS for use in non-CF bronchiectasis. METHODS: This study included outpatients with radiologically proven bronchiectasis and no evidence of CF. Results of LRTI-VAS were compared with other markers of disease activity {lung function parameters, oxygen saturation and three health-related quality of life questionnaires [Medical Outcomes Study Short-Form 36 Health Survey (SF-36), St Georges Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ)]} and validity, reliability and responsiveness were assessed. RESULTS: Thirty stable and 30 exacerbating participants completed the LRTI-VAS questionnaire. When testing for repeatability on two separate occasions, no statistically significant difference between total scores was found {1.4 [standard deviation (SD)] 5.3}, P = 0.16). Internal consistency was high across items (Cronbach's alpha 0.86). Correlation with SGRQ, SF-36 and LCQ total scores was high. Following antibiotic treatment, mean (SD) LRTI-VAS total score improved from 18.1 (SD 9.9) to 26.1 (SD 6.6) (P < 0.001). CONCLUSIONS: LRTI-VAS showed excellent validity, reliability and responsiveness to change and therefore appears a reliable tool for symptom measurement in non-CF bronchiectasis.
Authors: Hendrik Johannes Prins; Ruud Duijkers; Johannes M A Daniels; Thys van der Molen; Tjip S van der Werf; Wim Boersma Journal: BMJ Open Respir Res Date: 2021-02
Authors: Bridget C Howard; Hayden McRobbie; Dennis Petrie; Daniel Barker; Colin Mendelsohn; Jack Anderson; Ron Borland; Felix Naughton; Piotr Tutka; Nick Zwar; Veronica C Boland; Alexandra Aiken; Anthony Shakeshaft; Coral Gartner; Robyn L Richmond; Wayne Hall; Richard P Mattick; Michael Farrell; Ryan J Courtney Journal: Trials Date: 2022-09-14 Impact factor: 2.728
Authors: Rebecca H McLeese; Arietta Spinou; Zina Alfahl; Michail Tsagris; J Stuart Elborn; James D Chalmers; Anthony De Soyza; Michael R Loebinger; Surinder S Birring; Konstantinos C Fragkos; Robert Wilson; Katherine O'Neill; Judy M Bradley Journal: Eur Respir J Date: 2021-11-11 Impact factor: 16.671